Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (December 2024)
29 slides from Pluri's investor presentation, December 2024
Slide 1: Investor Presentation Q4 2024
Nasdaq: PLUR TASE: PLUR.TA INVESTOR PRESENTATION Q4 2024
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Solutions for Humanity's Greatest Challenges
AGING AND HEALTH CLIMATE CHANGE FOOD SECURITY SUSTAINABILITY SOLUTIONS FOR HUMANITY’S GREATEST CHALLENGES WE OFFER ROBUST CELL EXPANSION TECHNOLOGY PLATFORMS THAT CREATE NEW CELL-BASED SOLUTIONS. OUR TECHNOLOGY HAS THE POTENTIAL TO IMPROVE QUALITY OF LIFE AND MAKE OUR WORLD A BETTER PLACE. 3
Slide 4: Pluri at a Glance
PLURI AT A GLANCE COMPANY INDUSTRIES PARTNERS ● Nasdaq (PLUR), TASE (PLUR.TA) ● Cash & deposits: ~$27 million (as of September 30, 2024) Regenerative medicine: Cultivated meat ● Based in Israel with global presence, cell therapies collaboration with Tnuva including in the USA and Europe and other gl
Slide 5: Our Greatest Asset
OUR GREATEST ASSET The Pluri technology platforms leverage the basic building blocks of life—cells—to create medicine, food and cell-based materials that can change the course of human history. TECHNOLOGY ADVANTAGES Patented, proprietary 3D cell expansion technology to produce high-quality cells in
Slide 6: PluriMatrix™
PLURIMATRIX™ PluriMatrix™ is a breakthrough system for unprecedented industrial scale production of cell-based products PLURIMATRIX™ ADVANTAGES Significantly increases industrial scale production of cell-based products by using a packed-bed system Flexible production to power a range of cell-based p
Slide 7: Business Development Strategy
BUSINESS DEVELOPMENT STRATEGY Development and Partnerships that manufacturing of leverage Pluri’s innovative cell-based technology to meet cell- products using Pluri’s based manufacturing 3D cell expansion needs for a variety of technology industries 7
Slide 8: Pluri's Cell Expansion Technology Platforms
PLURI’S CELL EXPANSION TECHNOLOGY PLATFORMS ONE TECHNOLOGY, MANY The potential applications SOLUTIONS are almost endless. Any industry that requires mass cell production can potentially benefit from Pluri’s patented technology. 8
Slide 9: Our Mission
OUR MISSION To leverage our advanced cell expansion platforms and position as a global leader in cell technology to develop, manufacture and market highly effective cell-based products and solutions that enhance global wellbeing and promote sustainability And many other industries… 9
Slide 10: 11
11
Slide 11: Cell-Based Is Better
CELL-BASED IS BETTER Cell expansion technology produces mass scale, cost- effective food products in an efficient and sustainable manner ENVIRONMENTAL ETHICAL CONSUMER Fast growing industry: ● Uses significantly less land and ● Adheres to ethical animal ● Facilitates natural flavor water than conven
Slide 12: Ever After Foods Milestones
EVER AFTER FOODS MILESTONES June 2024 March 2023 December 2022 $10 million strategic January investment round led by 2022 Ever After Foods leading global launches scalable corporates Joint venture platform for cost reaches POC effective production of • License extended to sustainable cultivated incl
Slide 13: 14
14
Slide 14: The Evolution of Pluri's 3D Cell-Expansion Technology Platforms
THE EVOLUTION OF PLURI’S 3D CELL- EXPANSION TECHNOLOGY PLATFORMS ● Nearly 20 years of experience perfecting a manufacturing process to grow cells efficiently in mass quantities ● Developing an innovative line of cell therapy product candidates in regenerative medicine to treat unmet medical needs ●
Slide 15: Unlocking the Power of Immunotherapy
UNLOCKING THE POWER OF IMMUNOTHERAPY Immunotherapy uses a person's own immune system to fight illness. In recent years the field of CAR-T has been gaining momentum for the treatment of cancer as well as viral infection and autoimmune diseases. There is no approved cell-based therapy for solid tumors
Slide 16: PLX-R18 for Acute Radiation Syndrome (ARS)
PLX-R18 FOR ACUTE RADIATION SYNDROME (ARS) Significant increase in survival rate (68%) versus placebo (p<0.0001) ARS, also known as radiation sickness or radiation poisoning, is caused by exposure to high amounts of ionizing radiation, such as in nuclear reactor accidents or warfare Significant incr
Slide 17: Advanced and Completed Clinical Studies
ADVANCED AND COMPLETED CLINICAL STUDIES PLX-R18 to stimulate the regeneration of damaged bone marrow following Hematopoietic Cell Transplantation (HCT) Positive Phase I results to demonstrate the safety and exploratory efficacy of PLX-R18 in humans reported March 2022 PLX-R18 reduced mortality from
Slide 18: Pluri Is Part of the PROTO Consortium
PLURI IS PART OF THE PROTO CONSORTIUM Phase I/IIa study* of PLX-PAD for the treatment of mild to moderate knee osteoarthritis (OA) Pluri is part of PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by Charité Berlin to develop PLX-PAD for OA OA is one of
Slide 19: CDMO
e e pluricdma
Slide 20: Pluri's Contract Development Manufacturing Organization
PLURI’S CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATION We work with our partners from preclinical EXPERTISE EXPERIENCE FACILITY & LOGISTICS development to • Pluri’s team is experienced • Reliable logistics links and • Deep process and analytical commercialization, to development expertise in multip
Slide 21: Facility Overview
FACILITY OVERVIEW • With more than 15 years of GMP manufacturing expertise, Pluri is leveraging its skilled team, 4,400m² facility and logistics capabilities for cell therapy CDMO clients • GMP manufacturing facility compliant to Europe, USA and Israel standards o Local presence in Europe and USA fo
Slide 22: Agtech
agtech cdmo 24
Slide 23: The Coffee Crisis
THE COFFEE CRISIS CLIMATE CHANGE • Global coffee production will decrease by half in the next 30 years due to global warming PRICE INSTABILITY • US coffee import prices have risen by over 65% • Prices changed from 390 cents per kg to 624 and back to 419 cents per kg (2009-2023) LAND SHORTAGE • Land
Slide 24: Pluri's Cell-Based Coffee
PLURI’S CELL-BASED COFFEE PATENTED SUSTAINABLE COFFEE COFFEE CELL TECH Pioneering production 3D plant cell cultivation, for a sustainable and license to use Pluri’s IP ethical alternative and know-how ECO-EFFICIENT EXPERIENCE MASS SCALE PRODUCTION Two decades of experience and a Reducing carbon prof
Slide 25: Collaborations with Multi-National Agricultural Corporations
COLLABORATIONS WITH MULTI-NATIONAL AGRICULTURAL CORPORATIONS ICL and Pluri are partnering to develop new plant nutrition solutions. They will create bioactive carriers and biostimulants to improve crop yield using natural delivery mechanisms in plants. Pluri partnered with a major agriculture corpor
Slide 26: Significant Support from Leading Organizations
SIGNIFICANT SUPPORT FROM LEADING ORGANIZATIONS REGULATORY SCIENTIFIC COLLABORATIONS AND PARTNERING FUNDING 29
Slide 27: Commitment to Excellence
COMMITMENT TO EXCELLENCE Yaky Yanay Liat Zalts Lior Raviv Dr. Michal Sheleg, PhD Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Technology Officer VP Clinical Development Chief Commercial Officer Dr. Arthur Machlenkin, PhD Efrat Livne-Hadass Orly Amiran Efrat Kaduri John Dvor Chief Sci
Slide 28: Making a Positive Impact
MAKING A POSITIVE IMPACT* Healthcare Foodtech Work & Community Reduced Environmental Footprint Male 3% Up to Up to 93% Male Disabled Female 37% Female 32% 11% 3% 95% 78% Decrease 63% 68% Employees Less land Less water Air Pollution Employees Management Minority Disabled As the average age increases,
Slide 29: The Promise & the Opportunity
THE PROMISE & THE OPPORTUNITY Pluri’s cell-expansion technology will touch and improve every aspect of our lives. Promoting sustainability, wellbeing and improving quality of life. For every one of us. Individually. And for all of us, as a society. Together. For further information contact: investor